HK Stock Market Move | HENLIUS (02696) is now up more than 4%, POHERDY has been approved for listing in the United States, covering all indications of original research products.

HENLIUS (02696) is currently up more than 4%, as of the time of writing, up 4.11% to 67.1 Hong Kong dollars, with a turnover of 31.4021 million Hong Kong dollars. In terms of news, HENLIUS and Organon jointly announced that the biological product license application for the pertuzumab injection POHERDY has been approved by the U.S. Food and Drug Administration (FDA). It can be used interchangeably with the original product PERJETA, becoming the first and only PERJETA biosimilar in the United States, covering all indications approved for the original product in the United States. It is reported that POHERDY is the first biosimilar pertuzumab in the United States, and also the first interchangeable biosimilar drug approved by the FDA for the treatment of cancer. HLX11 has also submitted applications for listing in China, Europe, and Canada and has been accepted. As of now, HENLIUS has had 7 products approved for overseas listing, with 4 products approved for listing in the United States.